Extracellular Vesicle-Loaded Oncogenic lncRNA NEAT1 from Adipose-Derived Mesenchymal Stem Cells Confers Gemcitabine Resistance in Pancreatic Cancer via miR-491-5p/Snail/SOCS3 Axis.


Journal

Stem cells international
ISSN: 1687-966X
Titre abrégé: Stem Cells Int
Pays: United States
ID NLM: 101535822

Informations de publication

Date de publication:
2023
Historique:
received: 13 09 2022
revised: 07 12 2022
accepted: 22 12 2022
entrez: 10 2 2023
pubmed: 11 2 2023
medline: 11 2 2023
Statut: epublish

Résumé

It is becoming increasingly evident that key mechanisms of mesenchymal stem cell (MSC) efficacy appear to associate with paracrine activities, and the delivery of cargos through extracellular vesicles (EVs) controls the mechanistic actions of MSCs. Thus, this study clarified a possible mechanism by which EV-encapsulated NEAT1 from adipose-derived mesenchymal stem cells (ADSCs) might mediate gemcitabine resistance in pancreatic cancer (PCa). Microarray profile suggested a differentially expressed lncRNA NEAT1 in PCa, and we determined its expression in PCa cells. NEAT1 was found to be upregulated in PCa. The binding affinity among NEAT1, miR-491-5p, and Snail was identified through bioinformatic analysis and experimental validation. NEAT1 competitively bound to miR-491-5p to elevate Snail expression and diminish SOCS3 expression. PCa cells were cocultured with EVs extracted from ADSCs, followed by assessment of malignant phenotypes, tumorigenesis, and gemcitabine resistance of PCa cells using gain- or loss-of-function experiments. ADSC-derived EVs carrying NEAT1 promoted PCa cell proliferation, migration, and gemcitabine resistance

Identifiants

pubmed: 36762032
doi: 10.1155/2023/6510571
pmc: PMC9902843
doi:

Types de publication

Journal Article

Langues

eng

Pagination

6510571

Informations de copyright

Copyright © 2023 Rongxiang Wu et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

World J Gastroenterol. 2019 Oct 7;25(37):5590-5603
pubmed: 31602160
Molecules. 2012 Dec 11;17(12):14733-47
pubmed: 23519249
Cell Death Differ. 2016 Apr;23(4):616-27
pubmed: 26794444
Mol Cancer. 2018 Jan 05;17(1):2
pubmed: 29304816
Nat Commun. 2018 Jan 15;9(1):191
pubmed: 29335551
Lancet. 2020 Jun 27;395(10242):2008-2020
pubmed: 32593337
Sci Rep. 2017 Jul 18;7(1):5708
pubmed: 28720759
Cell Stem Cell. 2012 Jul 6;11(1):50-61
pubmed: 22770241
Am J Cancer Res. 2016 Oct 01;6(10):2361-2374
pubmed: 27822425
Int J Mol Sci. 2017 Jul 26;18(8):
pubmed: 28933761
Front Oncol. 2020 Jun 23;10:1013
pubmed: 32656089
Biomedicines. 2020 Aug 03;8(8):
pubmed: 32756339
Clin Cancer Res. 2021 Jun 15;27(12):3383-3396
pubmed: 33674273
World J Gastroenterol. 2015 Jul 14;21(26):7988-8003
pubmed: 26185370
Cardiovasc Res. 2012 Aug 1;95(3):346-55
pubmed: 22687273
Stem Cell Res Ther. 2019 Aug 7;10(1):242
pubmed: 31391108
Biomolecules. 2021 Apr 26;11(5):
pubmed: 33925948
Cancers (Basel). 2021 Nov 12;13(22):
pubmed: 34830825
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Cancer. 2017 Nov 1;123(21):4158-4167
pubmed: 28708929
Mol Cancer. 2020 Mar 2;19(1):49
pubmed: 32122376
Theranostics. 2019 Sep 21;9(23):6901-6919
pubmed: 31660076
JCI Insight. 2021 Mar 8;6(5):
pubmed: 33539327
Cancer Sci. 2021 Dec;112(12):4987-4999
pubmed: 34628696
Biosci Rep. 2019 Jan 30;39(1):
pubmed: 30135141
J Exp Clin Cancer Res. 2019 Aug 13;38(1):350
pubmed: 31409387
Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194
pubmed: 30608598
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Mol Cancer. 2020 Jul 29;19(1):118
pubmed: 32727463
Cell Death Dis. 2019 Feb 15;10(3):153
pubmed: 30770779
Cells. 2021 Aug 18;10(8):
pubmed: 34440886
Theranostics. 2018 Jun 24;8(14):3932-3948
pubmed: 30083271
Cancer Res. 2021 Nov 15;81(22):5678-5691
pubmed: 34593522
Cancer Lett. 2021 Nov 1;520:1-11
pubmed: 34216688
J Gene Med. 2021 Jun;23(6):e3333
pubmed: 33789360
Cell Biosci. 2019 Jul 01;9:54
pubmed: 31304004
Mol Cancer. 2019 Jul 19;18(1):119
pubmed: 31324186
Cells. 2021 Jun 01;10(6):
pubmed: 34205944
Am J Cancer Res. 2021 Aug 15;11(8):3841-3856
pubmed: 34522453
Nat Commun. 2017 Jun 01;8:15080
pubmed: 28569747
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Int J Mol Sci. 2021 Oct 10;22(20):
pubmed: 34681603
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514451
Cell Death Dis. 2021 Oct 20;12(11):973
pubmed: 34671031
Exp Ther Med. 2017 Nov;14(5):4773-4780
pubmed: 29201179
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Genome Biol. 2019 Jan 14;20(1):12
pubmed: 30642385
J Clin Invest. 2016 Apr 1;126(4):1152-62
pubmed: 27035807
Cancer Med. 2019 Oct;8(14):6403-6413
pubmed: 31475468
Mol Ther Nucleic Acids. 2018 Dec 7;13:472-482
pubmed: 30388621
Pharmacology. 2021;106(3-4):143-153
pubmed: 32966993
J Cancer. 2021 Jul 25;12(18):5622-5632
pubmed: 34405022
J Transl Med. 2013 Jan 17;11:18
pubmed: 23324136
Am J Cancer Res. 2020 Jan 01;10(1):237-248
pubmed: 32064164
Biochem Biophys Res Commun. 2017 Jan 22;482(4):828-834
pubmed: 27888106
Front Oncol. 2021 Nov 19;11:671082
pubmed: 34868904

Auteurs

Rongxiang Wu (R)

Jiangsu University, Zhenjiang 212013, China.

Zhan Su (Z)

Department of Hepatopancreatobiliary Surgery, Xuzhou Cancer Hospital, Xuzhou 221005, China.

Le Zhao (L)

Department of Hepatopancreatobiliary Surgery, Xuzhou Cancer Hospital, Xuzhou 221005, China.

Ruifeng Pei (R)

Department of Hepatopancreatobiliary Surgery, Xuzhou Cancer Hospital, Xuzhou 221005, China.

Yiren Ding (Y)

Department of Hepatopancreatobiliary Surgery, Xuzhou Cancer Hospital, Xuzhou 221005, China.

Deqiang Li (D)

Department of Hepatopancreatobiliary Surgery, Xuzhou Cancer Hospital, Xuzhou 221005, China.

Shuo Zhu (S)

Department of Hepatopancreatobiliary Surgery, Xuzhou Cancer Hospital, Xuzhou 221005, China.

Lu Xu (L)

Department of Hepatopancreatobiliary Surgery, Xuzhou Cancer Hospital, Xuzhou 221005, China.

Wei Zhao (W)

Department of Hepatopancreatobiliary Surgery, Xuzhou Cancer Hospital, Xuzhou 221005, China.

Wuyuan Zhou (W)

Department of Hepatopancreatobiliary Surgery, Xuzhou Cancer Hospital, Xuzhou 221005, China.

Classifications MeSH